Camurus announces new Phase 3 data reinforcing long-term safety and efficacy of octreotide SC depot (CAM2029) in patients with acromegaly
/PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced topline, interim data from an open-label, long-term safety and extension trial, ACROINNOVA 2,...
Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
/PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announces that the US Food and Drug Administration (FDA) has approved Brixadi™ (buprenorphine) extended...
Cambiar Investors Launches Aggressive Value ETF
Cambiar Investors, a leading global relative value manager, today announced the launch of the Cambiar Aggressive Value ETF (NYSE Arca: CAMX), a new actively managed exchange-traded fund providing investors...